Strategic partnership Exclusive U.S. market distribution potential through Legacymedicalconsultants partnership to accelerate ActiGraft adoption in the United States and leverage local sales channels.

Autologous Advantage ActiGraft Pro uses patient blood, aligning with trends in personalized medicine and reducing reliance on synthetic wound care products, which can be a strong differentiator to win hospital procurement and payer interest.

Regulatory Readiness Recent product launches and ongoing financing indicate momentum; position sales efforts to target expanding regulatory approvals, reimbursements, and clinician education to accelerate commercialization.

Midmarket Opportunity Revenue in the low-to-mid millions with a compact team suggests scalable channels through distributors and consultative selling to wound care centers, long-term care facilities, and hospitals seeking advanced wound care solutions.

Market Expansion Track growing demand for advanced wound care and compatibility with existing wound care protocols; emphasize cost-savings, faster healing outcomes, and reduced bandage dependency to drive trial adoption.